Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
MEF2D is a member of the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. Additionally we are shipping MEF2D Proteins (6) and MEF2D Kits (1) and many more products for this protein.
Showing 10 out of 139 products:
Dog (Canine) Monoclonal MEF2D Primary Antibody for IF, IP - ABIN968169
Breitbart, Liang, Smoot, Laheru, Mahdavi, Nadal-Ginard: A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage. in Development (Cambridge, England) 1994
Show all 4 Pubmed References
Dog (Canine) Monoclonal MEF2D Primary Antibody for IF, IP - ABIN968170
Guttridge, Mayo, Madrid, Wang, Baldwin: NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. in Science (New York, N.Y.) 2000
Show all 4 Pubmed References
Human Polyclonal MEF2D Primary Antibody for IHC - ABIN966557
Zhao, New, Kravchenko, Kato, Gram, di Padova, Olson, Ulevitch, Han: Regulation of the MEF2 family of transcription factors by p38. in Molecular and cellular biology 1999
Show all 6 Pubmed References
Human Polyclonal MEF2D Primary Antibody for IHC - ABIN966558
Wang, Bertos, Vezmar, Pelletier, Crosato, Heng, Thng, Han, Yang: HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. in Molecular and cellular biology 1999
Show all 6 Pubmed References
In summary, we found that miR (show MLXIP Antibodies)-1244 affected cisplatin-treated non-small cell lung cancer via MEF2D expression.
MEF2d mRNA level is up-regulated in both sporadic and SOD1 + ALS patients.
MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases.
HIF-1alpha (show HIF1A Antibodies) transactivates MEF2D expression by binding to the MEF2D gene promoter to induce angiogenesis in colorectal tumors.
MEF2D directly regulated transcription of the epithelial-mesenchymal transition driver gene ZEB1 (show ZEB1 Antibodies) and facilitated histone acetylation at the ZEB1 (show ZEB1 Antibodies) promoter in colorectal cancer cells
MEF2D-BCL9 (show BCL9 Antibodies)-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9 (show HDAC9 Antibodies).
These results suggest that PPARgamma (show PPARG Antibodies) may exert its antiproliferative effects by negatively regulating the MEF2D in CM cells, which through upregulation of miR (show MLXIP Antibodies)-122, and PPARgamma (show PPARG Antibodies)/miR (show MLXIP Antibodies)-122/MEF2D signaling pathway may be a novel target for treatment of CM.
MEF2D overexpression participated in the growth of lung cancers and its aberrant expression may result from the reduction of tumor suppressor miR (show MLXIP Antibodies)-218.
MEF2D is a direct target of miR (show MLXIP Antibodies)-19.
We found that in malignant glioma, there is an aberrantly high expression of MEF2D, which leads to poor prognosis of malignant glioma. The downregulation of MEF2D suppresses the proliferation of malignant glioma cell lines by inducing delay of S and G2/M phases of cell cycle and promoting apoptosis.
These findings uncover a novel role for Mef2c (show MEF2C Antibodies)/d in coordinating the transcriptional network that promotes early B-cell development.
This study identifies MEF2D as a critical regulator of IL-10 (show IL10 Antibodies) gene expression that negatively controls microglia inflammation response and prevents inflammation-mediated cytotoxicity.
Mef2d is essential for the maturation and integrity of retinal photoreceptor and bipolar cells
miR (show MLXIP Antibodies)-103 worked through activating AKT (show AKT1 Antibodies)/mTOR (show FRAP1 Antibodies) signal pathway and impairing target gene MEF2D.
These findings demonstrate that broadly expressed TFs acquire specific functions through competitive recruitment to enhancers by tissue-specific Mef2d and through selective activation of these enhancers to regulate tissue-specific genes.
Whereas MEF2A (show MEF2A Antibodies) is absolutely required for proper myoblast differentiation, MEF2B (show MEF2B Antibodies), -C, and -D were found to be dispensable for this process.
A role for endogenous MEF2 (show MEF2C Antibodies) factors exclusively in hormone/Fsk/cAMP-induced Nr4a1 (show NR4A1 Antibodies) gene expression in mouse MA-10 Leydig cells.
Oxidation of survival factor MEF2D inhibits its function, underlies oxidative stress-induced (show SQSTM1 Antibodies) neurotoxicity, and may be a part of the Parkinson disease pathogenic process.
Results demonstrate that coordinated alternative splicing by a single RNA binding protein modulates transcription (Mef2d) and cell signaling (Rock2 (show ROCK2 Antibodies)) programs to drive tissue-specific functions (cell fusion) to promote a developmental transition.
We found that Parkinson's disease -associated neurotoxins destabilize MEF2D mRNA and reduce its level in vitro and in vivo.
Expression analysis showed that the MEF2D polymorphisms were highly correlated with MEF2D mRNA and protein levels in the longissimus dorsi muscle of Polish Holstein-Friesian bulls carrying the three different combined genotypes.
This gene is a member of the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. Members of this family are involved in control of muscle and neuronal cell differentiation and development, and are regulated by class II histone deacetylases. Fusions of the encoded protein with Deleted in Azoospermia-Associated Protein 1 (DAZAP1) due to a translocation have been found in an acute lymphoblastic leukemia cell line, suggesting a role in leukemogenesis. The encoded protein may also be involved in Parkinson disease and myotonic dystrophy. Alternative splicing results in multiple transcript variants.
myocyte enhancer factor 2D
, MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D)
, myocyte-specific enhancer factor 2D-like
, MADS box transcription enhancer factor 2, polypeptide D
, myocyte-specific enhancer factor 2D